A NOVEL VACCINE AGAINST HEAMOPHILUS PARASUIS
The invention pertains to a serine protease antigen which induces antibodies against a protein having at least 69% sequence identity with the Heamophilus parasuis protein according to SEQ ID No: 1, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis by administering a vaccine to the pig, wherein the vaccine comprises the serine protease antigen. The invention also pertains to a vaccine, a method to manufacture such a vaccine and a method to protect a pig against H. parasuis.
1 - 13 . (canceled)
14 . A method to protect a pig against an infection with Haemophilus parasuis comprising administering to the pig a vaccine that comprises a serine protease antigen that induces antibodies against a protein comprising an amino acid sequence that has at least 69% sequence identity with an Heamophilus parasuis protein comprising the amino acid sequence of SEQ ID NO: 1.
15 . The method of claim 14 , wherein the serine protease antigen induces antibodies against a protein comprising an amino acid sequence that has at least 90% sequence identity with the amino acid sequence of said Heamophilus parasuis protein.
16 . The method of claim 15 , wherein the serine protease antigen induces antibodies against a protein comprising an amino acid sequence that has at least 95% sequence identity with the amino acid sequence of said Heamophilus parasuis protein.
17 . The method of claim 14 , wherein said Heamophilus parasuis protein comprises a Mac-1 domain comprising the amino acid sequence of SEQ ID NO: 2 and the serine protease antigen comprises an amino acid sequence that has at least 70% identity with the amino acid sequence of said Mac-1 domain.
18 . The method of claim 17 , wherein the serine protease antigen comprises an amino acid sequence that has at least 80% identity with the amino acid sequence of said Mac-1 domain.
19 . The method of claim 18 , wherein the serine protease antigen comprises an amino acid sequence that has at least 90% identity with the amino acid sequence of said Mac-1 domain.
20 . The method of claim 19 , wherein the serine protease antigen comprises the amino acid sequence of the SEQ ID NO: 2.
21 . The method of claim 14 , wherein the serine protease antigen comprises an amino acid sequence that has at least 69% sequence identity with the amino acid sequence of said Heamophilus parasuis protein.
22 . The method of claim 14 , wherein said administering the vaccine to the pig protects the pig against an increased risk of mortality due to the infection with Haemophilus parasuis.
23 . The method of claim 14 , wherein said administering the vaccine to the pig protects the pig against one or more clinical signs due to the infection with Haemophilus parasuis.
24 . A vaccine to protect a pig against an infection with Haemophilus parasuis, comprising a serine protease antigen that induces antibodies against a protein comprising an amino acid sequence that has at least 69% sequence identity with an Heamophilus parasuis protein comprising the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier.
25 . The vaccine of claim 24 , wherein the serine protease antigen that induces antibodies against a protein comprising an amino acid sequence that has at least 90% sequence identity with the amino acid sequence of said Heamophilus parasuis protein, and a pharmaceutically acceptable carrier.
26 . The vaccine of claim 25 , wherein the serine protease antigen that induces antibodies against a protein comprising an amino acid sequence that has at least 95% sequence identity with the amino acid sequence of said Heamophilus parasuis protein, and a pharmaceutically acceptable carrier.